Tofidence™ (tocilizumab-bavi) injection
Approval Date: Sep 2023
Indicated for the treatment of rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs)
Cosentyx® (secukinumab) injection for intravenous use
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and other autoimmune conditions, this drug is now available in an intravenous formulation
Bimzelx® (bimekizumab-bkzx) injection for subcutaneous use
Approval Date: Oct 2023
Indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
Yuflyma™ (adalimumab-aaty) injection
Approval Date: May 2023
A biosimilar to Humira (adalimumab) this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis
Idacio® (adalimumab-aacf) injection
Approval Date: Dec 2022
Indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis
Tazorac® (tazarotene) gel
Approval Date: Sep 2022
Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement
Sotyktu™ (deucravacitnib) tablets
Approval Date: Sep 2022
Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Zoryve™ (roflumilast) cream
Approval Date: Jul 2022
Indicated for topical treatment of plaque psoriasis
Vtama® (tapinarof) cream
Approval Date: May 2022
A steroid-free topical indicated for treatment of plaque psoriasis
Riabni™ (rituximab-arrx)
Approval Date: Jun 2022
A biosimilar to Rituxan® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.
